Dr. Patel on Emerging Therapeutic Strategies in MCL

Video

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses emerging therapeutic strategies and ongoing research in mantle cell lymphoma (MCL).

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses emerging therapeutic strategies and ongoing research in mantle cell lymphoma (MCL).

Research with chimeric antigen receptor (CAR) T-cell therapy is still preliminary in MCL, but it will be interesting to see how the modality impacts the paradigm, explains Patel. As in other lymphomas, there is a lot of excitement about this approach, but in MCL, it is too early to understand what the role of that therapy will be.

Additionally, there is a lot of excitement surrounding readouts of the some of the combination studies that are now being done with BCL-2 inhibitors, adds Patel. For example, combinations of BTK inhibitors and BCL-2 inhibitors, such as ibrutinib (Imbruvica) and venetoclax (Venclexta). Those studies are being designed slightly differently than historical studies with a fixed duration of therapy. It will be insightful to see how different classes of therapy with potentially different toxicity profiles fare when combined with a BCL-2 inhibitor like venetoclax, concludes Patel.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD